Ocrelizumab – a monoclonal antibody – in the treatment of adult patients with multiple sclerosis: a systematic review
Aim: To analyze the efficacy, safety and pharmacoeconomic aspects of using ocrelizumab in adult patients with relapsing/remitting multiple sclerosis (R/R MS).Materials and Methods. We used the commonly accepted PICo(S) questionnaire with the following specifics: the population – patients with R/R MS...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | Russian |
Published: |
IRBIS LLC
2018-11-01
|
Series: | Фармакоэкономика |
Subjects: | |
Online Access: | https://www.pharmacoeconomics.ru/jour/article/view/261 |
id |
doaj-b6bb58345cfa4156b4150af64aa8d7d3 |
---|---|
record_format |
Article |
spelling |
doaj-b6bb58345cfa4156b4150af64aa8d7d32021-07-28T13:30:40ZrusIRBIS LLCФармакоэкономика2070-49092070-49332018-11-01113435610.17749/2070-4909.2018.11.3-043-056239Ocrelizumab – a monoclonal antibody – in the treatment of adult patients with multiple sclerosis: a systematic reviewD. L. Klabukova0M. E. Holownia-Voloskova1M. V. Davydovskaya2T. N. Ermolaeva3K. I. Polyakova4A. G. Fisun5K. A. Kokushkin6Research and Practical Center for Clinical Trials and Medical Technology Assessment, Moscow Department of Healthcare.Research and Practical Center for Clinical Trials and Medical Technology Assessment, Moscow Department of Healthcare.Research and Practical Center for Clinical Trials and Medical Technology Assessment, Moscow Department of Healthcare; N. I. Pirogov Russian National Research Medical University, Ministry of Health of Russia.Research and Practical Center for Clinical Trials and Medical Technology Assessment, Moscow Department of Healthcare.Research and Practical Center for Clinical Trials and Medical Technology Assessment, Moscow Department of Healthcare.Research and Practical Center for Clinical Trials and Medical Technology Assessment, Moscow Department of Healthcare.Research and Practical Center for Clinical Trials and Medical Technology Assessment, Moscow Department of Healthcare.Aim: To analyze the efficacy, safety and pharmacoeconomic aspects of using ocrelizumab in adult patients with relapsing/remitting multiple sclerosis (R/R MS).Materials and Methods. We used the commonly accepted PICo(S) questionnaire with the following specifics: the population – patients with R/R MS; the intervention – ocrelizumab; the comparators – all disease-modifying treatments for MS; the outcomes – the annualized relapse rate, confirmed disability progression, MRI results, quality-adjusted years of survival (QALYs), adverse events, and other clinical outcomes. The search for the relevant information was conducted in 2018 by using the embase, PubMed, Cochrane and eLibrary.ru databases and the «ocrelizumab» AND «multiple sclerosis» keywords. The levels of evidence and conclusiveness of the cited studies were also assessed.Results. Treatments with ocrelizumab resulted in a lower rate of disease progression as compared with interferon β -1a. As evidenced by a randomized clinical trial, the annualized relapse rate estimated after 96 weeks was lower with ocrelizumab than that with interferon β-1a (0.16 vs. 0.29, 47% decrease, p<0.001). For most secondary end points, patients on ocrelizumab showed better outcomes than those on interferon β-1a. In the ocrelizumab group, the most common adverse events were caused by reactions to the drug infusion, nasopharyngitis, upper respiratory and urinary tract infections, and headaches. No cases of progressive multifocal leukoencephalopathy have been reported so far. ocrelizumab is more clinically effective than the first-line disease-modifying therapies; this conclusion also refers to patients with the aggressive (highly active) form of MS. ocrelizumab showed the efficacy similar to the second-line disease-modifying therapies, but it had a more favorable safety profile. The pharmacoeconomic indices showed that using ocrelizumab had a positive impact on the budget in the long-term perspective.Conclusions. ocrelizumab can be considered as the main treatment alternative for patients with highly active MS and patients with a high risk of progressive multifocal leukoencephalopathy. However, an additional assessment of the risk caused by rare adverse events is needed.https://www.pharmacoeconomics.ru/jour/article/view/261ocrelizumabefficacysafetyrelapsing-remitting multiple sclerosisrelapsing multiple sclerosissecondary progressive multiple sclerosisanti-b-cell therapymonoclonal antibodies |
collection |
DOAJ |
language |
Russian |
format |
Article |
sources |
DOAJ |
author |
D. L. Klabukova M. E. Holownia-Voloskova M. V. Davydovskaya T. N. Ermolaeva K. I. Polyakova A. G. Fisun K. A. Kokushkin |
spellingShingle |
D. L. Klabukova M. E. Holownia-Voloskova M. V. Davydovskaya T. N. Ermolaeva K. I. Polyakova A. G. Fisun K. A. Kokushkin Ocrelizumab – a monoclonal antibody – in the treatment of adult patients with multiple sclerosis: a systematic review Фармакоэкономика ocrelizumab efficacy safety relapsing-remitting multiple sclerosis relapsing multiple sclerosis secondary progressive multiple sclerosis anti-b-cell therapy monoclonal antibodies |
author_facet |
D. L. Klabukova M. E. Holownia-Voloskova M. V. Davydovskaya T. N. Ermolaeva K. I. Polyakova A. G. Fisun K. A. Kokushkin |
author_sort |
D. L. Klabukova |
title |
Ocrelizumab – a monoclonal antibody – in the treatment of adult patients with multiple sclerosis: a systematic review |
title_short |
Ocrelizumab – a monoclonal antibody – in the treatment of adult patients with multiple sclerosis: a systematic review |
title_full |
Ocrelizumab – a monoclonal antibody – in the treatment of adult patients with multiple sclerosis: a systematic review |
title_fullStr |
Ocrelizumab – a monoclonal antibody – in the treatment of adult patients with multiple sclerosis: a systematic review |
title_full_unstemmed |
Ocrelizumab – a monoclonal antibody – in the treatment of adult patients with multiple sclerosis: a systematic review |
title_sort |
ocrelizumab – a monoclonal antibody – in the treatment of adult patients with multiple sclerosis: a systematic review |
publisher |
IRBIS LLC |
series |
Фармакоэкономика |
issn |
2070-4909 2070-4933 |
publishDate |
2018-11-01 |
description |
Aim: To analyze the efficacy, safety and pharmacoeconomic aspects of using ocrelizumab in adult patients with relapsing/remitting multiple sclerosis (R/R MS).Materials and Methods. We used the commonly accepted PICo(S) questionnaire with the following specifics: the population – patients with R/R MS; the intervention – ocrelizumab; the comparators – all disease-modifying treatments for MS; the outcomes – the annualized relapse rate, confirmed disability progression, MRI results, quality-adjusted years of survival (QALYs), adverse events, and other clinical outcomes. The search for the relevant information was conducted in 2018 by using the embase, PubMed, Cochrane and eLibrary.ru databases and the «ocrelizumab» AND «multiple sclerosis» keywords. The levels of evidence and conclusiveness of the cited studies were also assessed.Results. Treatments with ocrelizumab resulted in a lower rate of disease progression as compared with interferon β -1a. As evidenced by a randomized clinical trial, the annualized relapse rate estimated after 96 weeks was lower with ocrelizumab than that with interferon β-1a (0.16 vs. 0.29, 47% decrease, p<0.001). For most secondary end points, patients on ocrelizumab showed better outcomes than those on interferon β-1a. In the ocrelizumab group, the most common adverse events were caused by reactions to the drug infusion, nasopharyngitis, upper respiratory and urinary tract infections, and headaches. No cases of progressive multifocal leukoencephalopathy have been reported so far. ocrelizumab is more clinically effective than the first-line disease-modifying therapies; this conclusion also refers to patients with the aggressive (highly active) form of MS. ocrelizumab showed the efficacy similar to the second-line disease-modifying therapies, but it had a more favorable safety profile. The pharmacoeconomic indices showed that using ocrelizumab had a positive impact on the budget in the long-term perspective.Conclusions. ocrelizumab can be considered as the main treatment alternative for patients with highly active MS and patients with a high risk of progressive multifocal leukoencephalopathy. However, an additional assessment of the risk caused by rare adverse events is needed. |
topic |
ocrelizumab efficacy safety relapsing-remitting multiple sclerosis relapsing multiple sclerosis secondary progressive multiple sclerosis anti-b-cell therapy monoclonal antibodies |
url |
https://www.pharmacoeconomics.ru/jour/article/view/261 |
work_keys_str_mv |
AT dlklabukova ocrelizumabamonoclonalantibodyinthetreatmentofadultpatientswithmultiplesclerosisasystematicreview AT meholowniavoloskova ocrelizumabamonoclonalantibodyinthetreatmentofadultpatientswithmultiplesclerosisasystematicreview AT mvdavydovskaya ocrelizumabamonoclonalantibodyinthetreatmentofadultpatientswithmultiplesclerosisasystematicreview AT tnermolaeva ocrelizumabamonoclonalantibodyinthetreatmentofadultpatientswithmultiplesclerosisasystematicreview AT kipolyakova ocrelizumabamonoclonalantibodyinthetreatmentofadultpatientswithmultiplesclerosisasystematicreview AT agfisun ocrelizumabamonoclonalantibodyinthetreatmentofadultpatientswithmultiplesclerosisasystematicreview AT kakokushkin ocrelizumabamonoclonalantibodyinthetreatmentofadultpatientswithmultiplesclerosisasystematicreview |
_version_ |
1721273278954209280 |